Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 9/20 | 0.51 |
| ▸ | NPY1R | P25929 | 1/20 | 0.48 |
| ▸ | CCKBR | P32239 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6329323 | 0.91 | SCN9A (0.50) | SCN9ANPY1RCCKBR | |
| SCHEMBL25815593 | 0.89 | SCN9A (0.51) | SCN9ANPY1R | |
| SCHEMBL6328821 | 0.84 | SCN9A (0.45) | SCN9ANPY1RCCKBR | |
| SCHEMBL12376364 | 0.82 | SCN9A (0.69) | SCN9ANPY1RCCKBR | |
| SCHEMBL5638220 | 0.82 | SCN9A (0.69) | SCN9ANPY1RCCKBR | |
| SCHEMBL12376317 | 0.82 | SCN9A (0.69) | SCN9ANPY1RCCKBR | |
| SCHEMBL27057508 | 0.80 | ALDH1A1 (0.42) | SCN9ANPY1R | |
| SCHEMBL27057510 | 0.79 | ALDH1A1 (0.51) | — | |
| SCHEMBL25815779 | 0.79 | SLC6A2 (0.53) | SCN9A | |
| SCHEMBL6818187 | 0.79 | GAA (0.50) | SCN9ANPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6951872-B2 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-10-04 | — | — | US | disclosed |
| US-20040132718-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | JACOBSON IRINA C (US) | 2004-07-08 | — | — | US | disclosed |
| US-6710058-B2 | USE AS ANTICOAGULANT AGENTS FOR THERAPY AND PROPHYLAXIS OFTHROMBOEMBOLIC DISORDERS | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2004-03-23 | — | — | US | disclosed |
| EP-1337251-A1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002102380-A1 | MONOCYCLIC OR BICYCLIC CARBOCYCLES AND HETEROCYCLES AS FACTOR XA INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-12-27 | — | — | WO | disclosed |
| US-20020183324-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2002-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183324-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | F11, F12, SERPINC1 | SCN9A 292/4885NPY1R 859/4885CCKBR 353/4885 |
| US-20040132718-A1 | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors | F11, F12, SERPINC1 | SCN9A 292/4885NPY1R 859/4885CCKBR 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.